ArticleInternational journal of retina and vitreous2026
Longitudinal polarization diversity optical coherence tomography before and after photodynamic therapy in chronic central serous chorioretinopathy: a prospective clinical study.
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCentral serous chorioretinopathy (CSC) is the fourth most common retinopathy globally. Chronic central serous chorioretinopathy (cCSC) is a subtype of CSC characterized by persistent or recurrent subretinal fluid (SRF) for more than 3 months. CSC's pathophysiology is described by choriocapillaries (CC) hyperpermeability and vascular congestion. Photodynamic therapy (PDT) is the current treatment of choice for cCSC. PDT causes vascular remodelling by inducing reactive oxygen species (ROS). Melanin in the retinal pigment epithelium (RPE) is a major target of ROS and can be observed non-invasively using polarization-diversity OCT (PD-OCT). Fourier-domain mode-locked (FDML) OCT is an imaging modality that can be used for high-resolution imaging of choriocapillaries.Our study aimed to evaluate melanin-related depolarization and CC changes longitudinally before and after PDT in patients with cCSC.
methodsThis prospective clinical pilot study was conducted in accordance with the Declaration of Helsinki and approved by the institutional review board (REB H15-02914). 5 eyes with cCSC were imaged at baseline and within one hour, one week, and one month after half-dose PDT. Eligible patients had cCSC with active disease on multimodal imaging and no other major ocular comorbidities. Imaging included custom-built swept-source OCT angiography (OCTA) and polarization-diversity OCT (PD-OCT) and commercial SSOCT. PD-OCT depolarization was qualitatively assessed using degree of polarization uniformity (DOPU). PD-OCT volumes were manually segmented into: (1) the RPE layer (Inner RPE to outer Bruch's membrane), the full choroidal slab (Outer RPE to Choroidoscleral interface).
resultsPD-OCT revealed a decrease in DOPU after PDT across all patients. Manual segmentation of PD-OCT images showed that this effect was most prominent within the RPE-Bruch's Complex. The full choroidal slab demonstrated less depolarization post-PDT. FDML OCTA demonstrated transient flow alterations in the choriocapillaris within the same 4,000-µm PDT treatment zone. Immediately after PDT, FDML revealed irregular flow deficits and heterogeneous darkening across the choriocapillaris.
conclusionDOPU provides a novel, non-invasive marker for assessing RPE melanin integrity and may serve as a complementary tool for DOPU related changed following PDT in CSC. Our findings suggest a novel mechanism and transient effect of PDT action on RPE melanin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.